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Antonello Ganaue, Giuseppe Germano`f, Pasquale Innellid, Anna Painig,
Stefano Perlinih, Massimo Salvettig, Valerio Zaca`i, on behalf of the Gruppo di
Studio Ipertensione e Cuore, Societa’ Italiana di CardiologiaSystemic hypertension is highly prevalent in stable coronary
artery disease, a pervasive comorbidity complicating the
diagnostic performance and interpretation of non-invasive
provocative tests in chest pain patients because of the
ischaemic signals generated, despite normal or near normal
coronary arteries, by hearts structurally readapted by long-
term exposure to raised systemic blood pressure. Additional
and unresolved problems posed by arterial hypertension in
patients with stable coronary artery disease regard the
benefits of antihypertensive treatment due to reports of
irrelevant, if not detrimental, effect of blood pressure (BP)
lowering in averting coronary relapses as well as the lack of
association between BP levels and incident coronary events
in survivors from acute myocardial infarction. Uncertainties
extend to BP-independent cardioprotective effects of
antihypertensive drugs, although the efficacy of renin–
angiotensin system blockers in the long-term prevention of
cardiovascular events in stable coronary artery disease
patients has been shown by several studies, particularly
when combined with amlodipine, a dihydropiridine calcium
channel blocker. In contrast, the long-term effect of beta-1558-2027  2013 Italian Federation of Cardiologyblockers, the antihypertensive classmost used in that clinical
category, is not supported by strong evidence except that
generated in patients with systolic dysfunction and early
postmyocardial infarction recovery periods.
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Despite the almost universal recognition of its import-
ance as a coronary risk factor in healthy populations,1
several aspects of the impact of arterial hypertension
[blood pressure (BP) levels above a predefined cutoff,
usually 140/90mmHg, or ongoing antihypertensive treat-
ment] in patients with established coronary artery disease
(CAD) do not easily fit a simple cause–effect model.
Problematic aspects regard the immediate and early
phases of acute myocardial infarction (AMI) (see ref.2
for a review) and extend to stable CAD, a heterogeneous,
not mutually exclusive, clinical cluster including remote
acute coronary syndromes, prior percutaneous translum-
inal coronary angioplasty or coronary artery bypass graft
surgery, angiographically documented coronary stenosis
and stable angina. In all those conditions, arterial hyper-
tension affects about two-thirds of patients,3,4 a pervasive
comorbidity that mandates specific competence in hyper-
tension management as well as thoughtful awareness of
the underlying epidemiological and pathophysiological
interconnections. The concept is highlighted further by
the high rates of hypertension in the landmark random-
ized clinical trials (RCT),5–14 some of which are listed inTable 1, which dictated the evolution of treatment
strategies in the field.
On those premises, the present work will overview
critically some implications of arterial hypertension
in patients with stable CAD, a definition, this latter,
deliberately preferred to ischaemic heart disease that,
rather than a synonymous term, denotes more properly a
multifactorial and complex pathophysiological process of
which coronary atherosclerosis is only one component.15
CAD, instead, in referring to anatomic coronary status,
adapts better to the following discussion focused on
diagnostic studies ex post validated by coronary angio-
graphy16–28 as well as RCTs performed in patients care-
fully selected on the basis of obstructed epicardial
coronaries5–14 rather than ischaemic heart disease as
defined above.15
The non-invasive diagnosis of coronary artery
disease in hypertensive patients with chest
pain
Chest pain, either the typical retrosternal discomfort
triggered by physical exertion or emotional stress andDOI:10.2459/JCM.0b013e3283609332
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Correspondence between true-positive (i.e. sensitivity) and false-
positive (1-specificity) fraction of a binary diagnostic test and diagnostic
odds ratios (ORs). Diagnostic ORs differ quite markedly from those
used in epidemiological or intervention studies: for example, an OR of
3 (shaded area), a highly satisfactory outcome in those latter contexts,
profiles a poor diagnostic test that either mislabels about 60% of
controls at TPF¼0.80 or identifies only 25% or so of cases at
FPF¼0.10. Modified from34.
Table 1 Prevalence of history of hypertension (HT), acute myocardial infarction (AMI), percutaneous transluminal coronary angioplasty
(PTCA), coronary artery bypass graft surgery (CABG), treatment with beta-blockers (BB), calcium channel blockers (CCB), angiotensin-
converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in randomized clinical trials in stable coronary artery disease
published from 2000 onward listed by publication year
StudyRef N HT% AMI% Angina% PTCA% CABG% BB% CCB% ACEI/ARB%
HOPE5 9297 47 53 55 26 18 40 47 RAM
EUROPA6,a 12 218 25b 65 NR 29 29 63 32 PER
INVEST7 22 576 100 32 67 15 16 ATEN VER TRAN
CAMELOT8 1992 60 38 9d 28 8 76 AMLO ENAL
PEACE9 8290 46 55 70 41 39 60 36 TRAN
ACTION10 7865 51 50 93 20c Seec 80 NIF 22
COURAGE11 2287 67 38 85 38 15 89 40 59
BEAUTIFUL12,b 10 917 72 89 NR 51c Seec 87 NR 90
ONTARGET13 25 620 69 49 35 29 21 57 33 TEL
TRANSCEND14 5926 76 46 48 26 19 58 40 TEL
AMLO, amlodipine; ATEN, atenolol RAM, ENAL, enalapril; NIF, nifedipine; PER, perindopril; RAM, ramipril; TEL, telmisartan; TRAN, trandolapril; VER, verapamil refer to trial
drugs. ACTION10, A Coronary disease Trial Investigating Outcome with Nifedipine; BEAUTIFUL12, morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients
with coronary disease and left-ventricULar dysfunction; CAMELOT8, Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis; COURAGE11, Clinical
Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; EUROPA6, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery
disease; HOPE5, Heart Outcomes Prevention Evaluation; INVEST7, International Verapamil-Trandolapril Study; ONTARGET13, ONgoing Telmisartan Alone and in
combination with Ramipril Global EndpoinT; PEACE9, Prevention of Events with Angiotensin Converting Enzyme Inhibition; TRANSCEND14, The Telmisartan Randomised
AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease. a BP>160/90 mmHg or ongoing antihypertensive treatment. b Stable CAD &EF<40%.
c Relative percentages of PCI vs. CABG not reported. d Canadian Cardiovascular Society class 4 (angina at any level of physical exertion).relieved by rest or nitroglycerin, or atypical in its pres-
entation, is an alarming symptom whose management
hinges around the documentation of inducible ischae-
mia,29 a temporally ordered sequence of regional per-
fusion defects, mechanical abnormalities and electrical
disturbances, respectively. That so-called ‘ischaemic
cascade’30 may be triggered in myocardial regions per-
fused by stenosed coronaries stressed by exercise or
pharmacological agents such as dobutamine (DOB), an
alpha-1 and beta-agonist, or dipyridamole (DIP), an
adenosine breakdown inhibitor. As a result of those
hyperaemic stimuli, blood flow diverts from ischaemic
to non-ischaemic territories and from subendo to sub-
epicardial areas and the ensuing flow heterogeneity,
which constitutes the pathophysiological background of
inducible ischaemia,30 evokes the diagnostic array of
scintigraphic, echocardiographic and electrocardio-
graphic changes familiar to all cardiologists. Not dissim-
ilar ischaemic signals, however, are generated in
hypertensive hearts readapted by long-term exposure
to raised systemic BP,31,32 thus complicating the
interpretation of non-invasive provocative tests used to
diagnose flow-limiting coronary stenoses.33 In that con-
text, the diagnostic performance of non-invasive provo-
cative tests for the identification of flow-limiting coronary
stenoses differs markedly, a behaviour better understood
by some preliminary explanation of the operating charac-
teristics of diagnostic tests.
The operating characteristics of diagnostic tests
A binary (either positive or negative; dubious results need
retesting) screening test aims both to maximize the
identification of positives (the so-called true positive
fraction, TPF, also known as sensitivity) and minimize
misclassification of negatives (the so-called false-positive
fraction, FPF, also known as 1-specificity), the twoparameters plotted in receiver operating characteristic
(ROC) curves (Fig. 1). Perhaps less known is that TPF
and FPF are univocally defined by their odds ratio
(OR, derived from the following relationship: [TPF/
(1TPF)] [(1FPF)/FPF]), a general index of the
strength of a relationship between binary data, be it
a diagnostic outcome (positive/negative), a risk factor
(present/absent) or a disease status (disease/no disease).34
CE: Namrta; JCM/201663; Total nos of Pages: 8;
JCM 201663
Hypertension and stable coronary artery disease Pedrinelli et al. 3Quite importantly, the ORs required for reasonable diag-
nostic accuracy are far larger than those needed to
hypothesize relevant cause–effect relationships in epi-
demiological or intervention studies (Fig. 1). Thus, only
unusually strong, independent risk factors can markedly
improve the distinction of healthy from diseased indi-
viduals, an important concept explaining why ‘emerging’
risk factors not provided of such strength, after initial
enthusiasm, are bound to be abandoned in daily clinical
practice.35
Positive predictive power (PPV, the ratio of true-positive
results to both true-positive and false-positive results),
that is the probability that a person with a positive test has
coronary stenosis at coronary angiography, is a next
qualifier of a diagnostic test heavily conditioned by dis-
ease prevalence according to the Bayes’ theorem of
conditional probability. Thus, PPV of a positive echo
DOB (assuming, as an example, the summary value of
TPF¼ 0.88 and FPF¼ 0.13 reported in Table 2), admi-
nistered in 1000 individuals, would average 36% if
disease prevalence is 5%, [44/(44þ 124)], in, say, a
younger, non-smoking hypertensive woman with atypical
chest pain, rising to 87%, [440/(440þ 65)], that is close to
certainty, for disease prevalence of 50% as in a middle-
aged hypertensive, dyslipidaemic male smoker with
typical chest pain, showing quite clearly the essential
contribution of clinical judgement to diagnostic work-up.Table 2 Performance of diagnostic stress tests for detection of flow-lim
verified by ex-post coronary angiography
Test OR N CAD N (%) TPF (%
EKG exercise stress 1.1 43 21 (49) 0.72
1.4 137 101 (74) 0.58
1.5 43 29 (67) 0.67
4.4 197 116 (59) 0.77
4.5 35 17 (49) 0.82
4.9 59 22 (37) 0.68
5.4 76 24 (31) 0.81
Median 4.4 590 330 (56) 0.72
echo DIP 15.8 101 57 (56) 0.61
15.8 76 24 (31) 0.61
23.3 43 29 (67) 0.67
36.8 35 17 (49) 0.82
171.0a 53 23 (43) 0.78
Median 23.3 308 150 (49) 0.73
echo DOB 13.2 84 66 (79) 0.73
23.4 101 57 (56) 0.88
35.9 30 18 (60) 0.93
76.9 76 24 (31) 0.87
147.4 197 116 (59) 0.75
171.0a 43 29 (67) 0.93
Median 56.4 531 310 (59.5) 0.88
SPECT 7.7 137 101 (74) 0.75
9.9 84 66 (79) 0.67
10.1 76 24 (31) 0.90
27.6 101 57 (56) 0.98
27.8 92 18 (20) 0.94
62.7 50 32 (64) 0.80
87.3 53 23 (43) 1.0
Median 27.6 593 340 (54) 0.90
Data on electrocardiogram (EKG) exercise stress test refer to studies in which the proc
artery disease prevalence; echo DIP, dipyridamole stress echocardiography; echo DOB
predictive value; OR, odds ratio; PPP, positive predictive values; SPECT, single-photon
maximum.In contrast to PPV, negative predictive value (NPV)
(the ratio of true-negative results to both true-negative
and false-negative results), that is the probability
that a person with a negative (N) test does not have a
disease as assessed by a golden standard, would be
unchanged in both conditions [88%; (827/(827þ 123)
and 435/(435þ 60), respectively] so that, independent
of disease prevalence and specificity, a negative out-
come obtained by a highly sensitive test would prac-
tically exclude significant obstructive epicardial coronary
disease.
The diagnostic performance of non-invasive stress tests
in hypertensive patients with chest pain
Table 2 provides the diagnostic ORs and other indicators
of diagnostic performance of non-invasive stress tests
for the detection of coronary stenoses in hypertensive
patients with chest pain. The table compiles a series of
angiographically validated studies comparing electro-
cardiogram (EKG) exercise stress, stress echocardio-
graphy and SPECT16–28 and does not refer to diagnostic
techniques still sparsely validated in hypertensive
patients, such as exercise echocardiography, nuclear com-
puted tomography, MRI and PET reviewed in previous
work, which the interested reader is referred to.33
The unsatisfactory specificity of EKG exercise stress test
as a screening test for CAD in hypertensive patients withiting coronary stenoses in hypertensive patients with chest pain as
) FPF (%) PPV (%) NPV (%) AuthorRef
0.71 49 52 Senior et al.16
0.49 77 30 Elhendy et al.17
0.58 71 38 Picano et al.18
0.43 72 63 Pasierski et al.19
0.50 61 75 Cortigiani et al.20
0.30 57 79 Maltagliati et al.21
0.44 46 86 Lu et al.22
0.50 61 63
0.09 90 64 Fragasso et al.23
0.09 76 83 Lu et al.22
0.08 95 57 Picano et al.18
0.11 88 84 Cortigiani et al.20
0 100 86 Astarita et al.24
0.09 90 84
0.17 94 46 Elhendy et al.25
0.20 85 84 Fragasso et al.23
0.27 84 87 Ariff et al.26
0.08 83 94 Lu et al.22
0.02 98 73 Pasierski et al.19
0 100 87 Senior et al.16
0.13 90 86
0.28 88 51 Elhendy et al.17
0.17 94 41 Elhendy et al.25
0.47 47 92 Lu et al.22
0.64 67 94 Fragasso et al.23
0.36 39 98 Prisant et al.27
0.06 96 73 Aggeli et al.28
0.53 59 100 Astarita et al.24
0.36 67 92
edure has been used for paired comparison with other stress tests. CAD, coronary
, dobutamine stress echocardiography; FPF, false-positive fraction; NPV, negative
emission computed tomography; TPF, true-positive fraction. a Approximated to the
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which are six to 10-fold lower than the other provocative
techniques. More specifically, the median FPF value of
0.50 reported in Table 2 implies that reliance upon EKG
exercise stress test would expose half of positives to
useless, costly and potentially risky medical procedures.
On the contrary, the median TPF of 0.72 means that one-
third or so of haemodynamically significant coronary
stenoses would not be detected, a poor result notably
obtained despite the high CAD prevalence (Table 2)
that, according to Bayes’s postulates, optimizes diagnos-
tic performance. Thus, EKG exercise stress test is neither
specific enough to identify reliably CAD when positive,
nor as sensitive as to exclude confidently its presence
when negative, an important limitation bailed out by its
potential in assessing exercise tolerance, chronotropic
and BP response, and long-term risk stratification.
Different conclusions are provided by DIP and DOB
stress echography whose specificity in hypertensive
patients is high enough to virtually exclude flow-limiting
coronary stenosis in case of negative results, albeit sen-
sitivity of the two tests differs in favour of DOB, an
advantage counterbalanced bymore frequent serious side
effects36 so that the choice between them should better
be left to the expertise developed at each single centre.
Table 2 also shows the performance of myocardial per-
fusion imaging that, despite its elevated sensitivity in the
detection of flow-limiting coronary stenoses in hyperten-
sive patients, is about four-fold less specific than stress
echography, a disadvantage amplified by the environ-
mental and long-term concerns related to the use of
radioactive tracers for myocardial imaging.37
Beyond their specific metrics, however, it should be kept
in mind that diagnostic performance is strongly affected
by selection (only more ‘worrying’ chest pain patients
tend to be referred for non-invasive and angiographic
screening) and verification (angiographic verification of
stenosis tends to be reserved to test-positives and with-
held in test-negatives) biases.38 Both attitudes likely
contributed to the unsatisfactory performance of provo-
cative tests for inducible ischaemia reported in a largely
hypertensive group of patients referred to angiography in
whom, quite disturbingly, preangiographic testing did
not raise the discriminatory power above that obtained
by clinical evaluation.39 On the contrary, adoption of
coronary angiography as a verification standard for ischae-
mic heart disease clearly led to labelling as false positives
a large portion of high-risk angina patients, women more
frequently,40 with ischaemic heart disease despite a
patent epicardial coronary tree.15
As a second consideration, stress tests have frequently
been applied to screen silent ischaemia in asymptomatic
hypertensive individuals with unfavourable risk profiles
but no prior history of ischaemic heart disease,41 an
approach based upon the background assumption thatunveiling and subsequent repair of advanced CAD at a
preclinical stage may prevent cardiac outcomes. How-
ever, that strategy is burdened, if applied on a large-scale
basis, by intolerable costs, considerable risks and being
unlikely to guarantee a consistent return at least as
compared with the benefits afforded by effective pharma-
cological treatments and lifestyle changes, for example.42
Although early identification of inducible ischaemia may
help to improve risk stratification,43 screening tests
should, however, do more than that,44 at least prompt
providers to increase use of evidence-based medical
therapies and patients to comply with their prescriptions,
two expectations unmet in a high-risk hypertension-
prone condition such as asymptomatic type 2 diabetes.45
As a result, diabetological guidelines now discourage
screening in asymptomatic diabetic patients,46 although
cardiological guidelines leave that option open in high-
risk individuals, but recommendations in the field are
highly inconsistent, with only a minority specifically
factoring cost into their algorithms.47
The management of hypertension in patients
with stable coronary artery disease
Although the benefits of antihypertensive treatment
are incontrovertible, it must be recognized that most of
the available evidence derives mainly from studies in
uncomplicated hypertensive patients48 extended by
inference to stable CAD. As a matter of fact, studies in
that specific setting specifically directed to evaluate BP
lowering vs. placebo are missing and the only trial target-
ing that category compared two different treatment regi-
mens7 and RCTs with angiotensin-converting enzyme
inhibitors (ACEIs),5,6,8,9 angiotensin II type 1 receptor
blockers (ARBs)13,14 and calcium channel blockers
(CCBs)8,10 were, rather paradoxically, carried out to test
BP-independent properties in mixed normotensive and
hypertensive cohorts. Thus, the positive long-term
results first reported with an ACEI such as ramipril in
the HOPE study,5 confirmed by some6 but not other
studies8,9 using different congeners, opened the way to
the use of ACEIs and possibly ARBs13,14 in stable CAD,49
an indication a fortiori stronger in the presence of
comorbid hypertension.49 With regard to CCBs, nifedi-
pine, a dihydropiridine (DHP) derivative and an effective
antihypertensive drug,48 was evaluated in patients with
stable angina pectoris10 in a trial that, while settling
concerns about its long-term safety in CAD patients,50
provided no evidence of long-term protection from hard
events.10 Similarly, verapamil, a phenylalkylamine CCB
derivative, combined with trandolapril, an ACEI, did not
differ from an atenolol along with hydrochlorothiazide-
based regimen in hypertensive patients with stable
CAD.7 Different from both drugs, amlodipine, a DHP
with potent antianginal properties51 and well tolerated in
severe congestive heart failure,52 decreased cardiovascu-
lar events as compared with both placebo and enalapril,
an ACEI8 (Fig. 2, left panel). Moreover, amlodipine in
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Left panel: Reduced cardiovascular event rate (cardiovascular death, non-fatal AMI, resuscitated cardiac arrest, coronary revascularization,
hospitalization for angina pectoris, hospitalization for congestive heart failure, fatal or non-fatal stroke or transient ischaemic attack, and peripheral
vascular disease) in stable CAD patients on amlodipine (AMLO) as opposed to the neutral effect of enalapril (ENAL), an ACEI. Right panel: No
difference in cardiovascular events (cardiovascular death, non-fatal MI or non-fatal stroke) in stable CAD patients on long-term beta-blockers (BB) or
not. Modified from8 and 4, respectively. ACEI, angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; CAD, coronary artery
disease; MI, myocardial infarction.combination with different ACEIs53,54 prevented cardio-
vascular events more effectively than a more conven-
tional diuretic along with ACEI53 or atenolol54-based
regimen in high-risk hypertensive patients, an outcome,
to some extent, consistent with posthoc analyses of the
EUROPA study.55 Thus, the association of amlodipine
with renin–angiotensin system inhibitors applies to first
choice treatment in stable CAD, a still inferential
hypothesis whose background evidence, though, is
stronger than that available for beta-blockers, the
pharmacological class by far most prescribed in stable
CAD patients (Table 1). Apart from systolic heart fail-
ure56 and early post-AMI recovery periods,57 in fact, theFig. 3
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is negative58 and their efficacy has been questioned even
in uncomplicated hypertension.59 Most recently, data
from the REACH study showed no difference between
CAD patients on beta-blockers and not (Fig. 2, right
panel), a result highly pertinent to the present context,
as patients included in that registry are hypertensive by
80%.4
A related but distinct problem raised by the coexistence
of arterial hypertension in stable CAD considers the
appropriateness to maintain BP at levels lower than
the 140/90mmHg cutoff conventionally accepted in25
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proposal, put forward only few years ago,60 equalized
stable CAD to diabetes and chronic renal failure for
which, at that time, BP values below 130/80mmHg or
less were recommended to achieve protection from
cardiovascular events.48 However, a reappraisal of all
trials of antihypertensive agents in patients with CAD
found no scientific ground for those recommendations,61
nowadays under revision even with regard to diabetes62
and chronic renal failure.63 Achievements of more strin-
gent BP targets in stable CAD also conflict with the poor
BP control characterizing daily clinical practice,64 lack of
association between BP levels with relapsing coronary
events in long-term follow-ups of post-AMI patients65
and recurring reports of the neutral,66 if not detrimental,67
effect of BP lowering on acute coronary events compen-
sated, to some extent, by a reduced stroke incidence.2 On
the contrary, it must be considered that raised systemic
BP values are merely one of the several and interacting
proatherogenic components of the hypertensive syn-
drome.1 Moreover, a hypertensive background unequi-
vocally compounds the negative prognostic impact
carried by inducible ischaemia per se68 (Fig. 3), although
the reasons for that noxious interaction are not clearcut.
Hypertension-related, more serious and/or faster progres-
sing atherosclerotic CAD may perhaps contribute to that
evolution, but, even were that the case, repair of the
diseased coronary segments does not seem to provide
the definitive therapeutic answer. In fact, coronary
revascularization in individuals with severe CAD has
provided uncertain results,69 apparently independent
of coexisting inducible ischaemia.70 Transluminal coron-
ary angioplasty, on the contrary, applied in patients with
less advanced CAD does not decrease death, myocardial
infarction rates or the need for subsequent revasculari-
zation71 as compared with optimal medical therapy,11 a
conclusion reminiscent of the outcome of renal angio-
plasty in the cognate field of atherosclerotic renovascular
disease.72
In conclusion, stress echocardiography provides a highly
sensitive and specific tool for the non-invasive identifi-
cation of haemodynamically significant coronary stenosis
in the hypertensive patient with chest pain in whom the
readaptation process in response to long-term exposure to
raised BP confounds the diagnostic process. However,
unanswered questions await responses such as, for
example, whether BP lowering benefits or not hyperten-
sive patients with stable CAD. Uncertainties extend to
cardioprotective effects of antihypertensive drugs,
although renin-angiotensin system blockers, particularly
when combined with amlodipine, a DHP calcium chan-
nel blocker, are promising in that regard. On the contrary,
no evidence supports at the moment the long-term use of
beta-blockers in that specific clinical category while
reopening of stenosed coronaries per se does not protect
from ischaemic relapses.Acknowledgements
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